<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id>
      <journal-title>Arthritis Research &amp; Therapy</journal-title>
      <issn pub-type="ppub">1478-6354</issn>
      <issn pub-type="epub">1478-6362</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">19735581</article-id>
      <article-id pub-id-type="pmc">2745804</article-id>
      <article-id pub-id-type="publisher-id">ar2784</article-id>
      <article-id pub-id-type="doi">10.1186/ar2784</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cytokines in the colon of a patient with Beh&#xE7;et's disease</article-title>
      </title-group>
      <contrib-group>
        <contrib id="A1" contrib-type="author">
          <name>
            <surname>Kappen</surname>
            <given-names>Jasper H</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>j.kappen@erasmusmc.nl</email>
        </contrib>
        <contrib id="A2" contrib-type="author">
          <name>
            <surname>Dik</surname>
            <given-names>Willem A</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>w.dik@erasmusmc.nl</email>
        </contrib>
        <contrib id="A3" contrib-type="author">
          <name>
            <surname>Dingjan</surname>
            <given-names>Gemma M</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>g.dingjan@erasmusmc.nl</email>
        </contrib>
        <contrib id="A4" contrib-type="author">
          <name>
            <surname>van Daele</surname>
            <given-names>Paul L</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>p.l.a.vandaele@erasmsumc.nl</email>
        </contrib>
        <contrib id="A5" contrib-type="author">
          <name>
            <surname>Hooijkaas</surname>
            <given-names>Herbert</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>h.hooijkaas@erasmusmc.nl</email>
        </contrib>
        <contrib id="A6" contrib-type="author">
          <name>
            <surname>van Hagen</surname>
            <given-names>P Martin</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>p.m.vanhagen@erasmusmc.nl</email>
        </contrib>
        <contrib id="A7" corresp="yes" contrib-type="author">
          <name>
            <surname>van Laar</surname>
            <given-names>Jan A</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>j.vanlaar@erasmusmc.nl</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Internal Medicine, Clinical Immunology Section, Erasmus MC, University Medical Center, room D419, 's Gravendijkwal 230, 3055CE, Rotterdam, The Netherlands</aff>
      <aff id="I2"><label>2</label>Department of Immunology, Erasmus MC, University Medical Center, room D419, 's Gravendijkwal 230, 3055CE, Rotterdam, The Netherlands</aff>
      <pub-date pub-type="ppub">
        <year>2009</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>8</month>
        <year>2009</year>
      </pub-date>
      <volume>11</volume>
      <issue>4</issue>
      <fpage>412</fpage>
      <lpage>412</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/11/4/412"/>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2009 BioMed Central Ltd</copyright-statement>
        <copyright-year>2009</copyright-year>
        <copyright-holder>BioMed Central Ltd</copyright-holder>
      </permissions>
    </article-meta>
    <notes>
      <p>See related research article by Ca&#xF1;ete <italic>et al.</italic>, <ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/11/1/R17"/> and related editorial by van Laar <italic>et al.</italic>, <ext-link ext-link-type="uri" xlink:href="http://arthritis-research.com/content/11/2/109"/></p>
    </notes>
  </front>
  <body>
    <sec>
      <title/>
      <p>We read with interest the article by Ca&#xF1;ete and colleagues [<xref ref-type="bibr" rid="B1">1</xref>] in a recent issue of <italic>Arthritis Research &amp; Therapy</italic>, in which they describe cytokine patterns of inflamed joints from patients with Beh&#xE7;et's disease (BD). The authors show that neutrophils and T lymphocytes are involved in a Th1-skewed inflammatory pattern expressed by elevations of interferon-gamma (IFN-&#x3B3;), tumor necrosis factor-alpha (TNF-&#x3B1;), and interleukin-2 (IL-2). Also, increased levels of IL-4, IL-10, and IL-17 were observed. We would like to add to these observations our data showing a similar cytokine profile in the colon of a patient with BD.</p>
      <p>A 37-year-old BD patient with severe colitis failed to respond to traditional immunosuppressive treatment. Steroids were contraindicated because of a previous retinal serosal ablation, probably induced by prednisone. TNF blockage initially successfully reduced the severity of the colitis, but relapses occurred. Variation of different TNF blockers (etanercept, infliximab, and adalimumab) could not permanently resolve the intestinal complaints. Antibodies against infliximab or adalimumab were not detected. Eventually, high-dose infliximab (10 mg/kg) and intravenous immunoglobulins (IVIGs) led to disease regression facilitating a hemicolectomy. Thereafter, the patient's condition improved significantly and IVIGs were terminated while TNF blockage was continued.</p>
      <p>Cytokines were evaluated in the resected colon by analyzing mRNA expression levels of cytokine genes as previously described [<xref ref-type="bibr" rid="B2">2</xref>]. Because of the extensive prior treatment, the patient served as an internal control. Intestinal inflammation was patchy, and the observed difference between healthy and diseased tissues was confirmed microscopically. The mRNA expression of cytokines in diseased colon is presented relative to that of healthy colon and can be seen as a reflection of intramural cytokines (Figure <xref ref-type="fig" rid="F1">1</xref>). Like Ca&#xF1;ete and colleagues, we observed a Th1- and Th17-skewed pattern (elevated IFN-&#x3B3; and TNF-&#x3B1; and elevated IL-17A, respectively). We could not demonstrate elevation of IL-10, possibly because our patient was intensively treated and the colon environment is not sterile.</p>
      <fig position="float" id="F1">
        <label>Figure 1</label>
        <caption>
          <p><bold>Relative mRNA expression of cytokine genes in affected colonic tissue of a patient with Beh&#xE7;et's disease</bold>. Diseased colonic tissue and healthy colonic tissue from the same patient were analyzed. IFN-&#x3B3;, interferon-gamma; IL, interleukin; TNF, tumor necrosis factor.</p>
        </caption>
        <graphic xlink:href="ar2784-1"/>
      </fig>
      <p>The immunopathology of BD remains fascinating and highly relevant to the development of future immune-directed therapy. Since the successful introduction of TNF blockers, it became apparent that Th1-cytokines might be key players in the immunopathology of BD, emphasizing the importance of cytokine studies [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Ca&#xF1;ete and colleagues [<xref ref-type="bibr" rid="B1">1</xref>] have highlighted the importance of tissue evaluation in cytokine studies. In this light, our data add to their observations that, in colonic tissue of a BD patient, IFN-&#x3B3;, TNF-&#x3B1;, and IL-17A appear to be key cytokines, even in a treated patient.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>BD: Beh&#xE7;et's disease; IFN-&#x3B3;: interferon-gamma; IL: interleukin; IVIG: intravenous immunoglobulin; TNF: tumor necrosis factor.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ca&#xF1;ete</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Celis</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Noordenbos</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Moll</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>G&#xF3;mez-Puerta</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Pizcueta</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Palacin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tak</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Sanmart&#xED;</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Baeten</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Distinct synovial immunopathology in Beh&#xE7;et disease and psoriatic arthritis</article-title>
          <source>Arthritis Res Ther</source>
          <year>2009</year>
          <volume>11</volume>
          <fpage>R17</fpage>
          <pub-id pub-id-type="pmid">19196489</pub-id>
          <pub-id pub-id-type="doi">10.1186/ar2608</pub-id>
        </citation>
      </ref>
      <ref id="B2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dik</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Nadel</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Przybylski</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Asnafi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Grabarczyk</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Navarro</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Verhaaf</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Macintyre</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>van Dongen</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Langerak</surname>
              <given-names>AW</given-names>
            </name>
          </person-group>
          <article-title>Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>110</volume>
          <fpage>388</fpage>
          <lpage>392</lpage>
          <pub-id pub-id-type="pmid">17360939</pub-id>
          <pub-id pub-id-type="doi">10.1182/blood-2006-12-064816</pub-id>
        </citation>
      </ref>
      <ref id="B3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yazici</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fresko</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Yurdakul</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Beh&#xE7;et's syndrome: disease manifestations, management, and advances in treatment</article-title>
          <source>Nat Clin Pract Rheumatol</source>
          <year>2007</year>
          <volume>3</volume>
          <fpage>148</fpage>
          <lpage>155</lpage>
          <pub-id pub-id-type="pmid">17334337</pub-id>
          <pub-id pub-id-type="doi">10.1038/ncprheum0436</pub-id>
        </citation>
      </ref>
      <ref id="B4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Laar</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Missotten</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>van Daele</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Jamnitski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Baarsma</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>van Hagen</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Adalimumab: a new modality for Beh&#xE7;et's disease?</article-title>
          <source>Ann Rheum Dis</source>
          <year>2007</year>
          <volume>66</volume>
          <fpage>565</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="pmid">17124248</pub-id>
          <pub-id pub-id-type="doi">10.1136/ard.2006.064279</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
